Ignite Creation Date:
2025-12-24 @ 4:28 PM
Ignite Modification Date:
2026-02-04 @ 12:23 AM
Study NCT ID:
NCT03365466
Status:
UNKNOWN
Last Update Posted:
2017-12-07
First Post:
2017-12-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Anticoagulation Therapies Effect on the Endometrial Blood Flow and Pregnancy Outcomes in Unexplained Recurrent Implantation Failure Women
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D001241', 'term': 'Aspirin'}, {'id': 'D006495', 'term': 'Heparin, Low-Molecular-Weight'}], 'ancestors': [{'id': 'D012459', 'term': 'Salicylates'}, {'id': 'D062385', 'term': 'Hydroxybenzoates'}, {'id': 'D010636', 'term': 'Phenols'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D006493', 'term': 'Heparin'}, {'id': 'D006025', 'term': 'Glycosaminoglycans'}, {'id': 'D011134', 'term': 'Polysaccharides'}, {'id': 'D002241', 'term': 'Carbohydrates'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 200}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2017-12', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-09', 'completionDateStruct': {'date': '2019-02', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-12-06', 'studyFirstSubmitDate': '2017-12-02', 'studyFirstSubmitQcDate': '2017-12-06', 'lastUpdatePostDateStruct': {'date': '2017-12-07', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-12-07', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Clinical pregnancy rate', 'timeFrame': 'until 12 weeks', 'description': 'Ongoing pregnancy beyond the 12th gestational week rate'}], 'secondaryOutcomes': [{'measure': 'Uterine artery blood flow', 'timeFrame': 'luteal phase before ET and one day before ET', 'description': 'by transvaginal sonography'}, {'measure': 'Implantation rate', 'timeFrame': '8 weeks', 'description': 'by transvaginal sonography'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['recurrent implantation failure', 'aspirin', 'low molecular weight heparin'], 'conditions': ['Recurrent Implantation Failure']}, 'descriptionModule': {'briefSummary': 'The aim of the study is to investigate whether Low Dose Aspirin and Low Molecular Weight Heparin could increase the uterine perfusion, and finally improve the implantation and pregnancy rates in patients with unexplained recurrent implantation failure.', 'detailedDescription': 'Infertility is a growing issue for many couples all over the world. Nowadays, Assisted reproductive technology is widely used to treat couples affected by infertility, but, the success rate is still very low. Recurrent implantation failure is an important cause of repeated IVF failure. In addition to the embryo quality, a functioning and receptive endometrium is crucial for embryo implantation. There is a growing amount of evidence shows that uterine perfusion playing an important part in regulating endometrial receptivity and in successful pregnancy.\n\nRecently, transvaginal ultrasonography is often used to examine endometrial thickness, pattern and blood flow status to predict uterine receptivity. Some studies have demonstrated that uterine artery blood flow resistance in RM (Recurrent miscarriage) patients is significantly higher than in normal fertile patients. It has been postulated that abnormal uterine perfusion could be related to the reproductive failure, enhancing the uterine perfusion may improve the successful pregnancy. In accordance with this hypothesis, some therapeutic approaches including low dose aspirin (LDA), nitric oxide donor, low molecular weight heparin, sildenafil are applying in clinic. Low molecular weight heparin (LMWH) is derived from unfractionated heparin. It also has anticoagulation or the antithrombin effect. Aspirin has analgesic, antipyretic, and anti-inflammatory properties. Initially, aspirin and low molecular weight heparin have been used either as single agents or in combination to treat patients with recurrent miscarriage, diagnosed with antiphospholipid syndrome. The treatment confers a significant benefit in live births rate. Furthermore, various studies have shown that thrombophilia are more common in women with RIF compared with healthy fertile controls. In these women, heparin treatment could potentially enhance the implantation process, and may finally improve the live birth rate. The aim of the study is to investigate whether Low Dose Aspirin and Low Molecular Weight Heparin could increase the uterine perfusion, and finally improve the implantation and pregnancy rates in patients with unexplained recurrent implantation failure.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT'], 'maximumAge': '45 Years', 'minimumAge': '25 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'This is a prospective cohort study on unexplained recurrent implantation failure patients with abnormal uterine perfusion in our clinic from September 2017 to December 2018.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. ≥3 pervious IVF-ET failures or failure with transfer of at least 10 frozen embryos in multiple transfers;\n2. 25-45 years old;\n3. Having a regular menstrual cycle and BBT;\n4. Top-quality frozen embryos for transfer;\n5. Endometrial thickness 8-14mm；\n6. Abnormal uterine perfusion(PI\\>2.5)；\n7. Decided to recieve LMWH or LDA or a combination of LMWH and LDA therapy.\n\nExclusion Criteria:\n\n1. Chromosome aberrations in anyone of the couple;\n2. Abnormal uterine cavity;\n3. Hydrosalpinx;\n4. Chronic systemic disease(liver,renal,heart,thyroid and thrombocytopenia)\n5. Having experienced severe allergies, trauma history；\n6. With a history of mental illness;\n7. Any contraindication for LDA or LMWH.'}, 'identificationModule': {'nctId': 'NCT03365466', 'briefTitle': 'Anticoagulation Therapies Effect on the Endometrial Blood Flow and Pregnancy Outcomes in Unexplained Recurrent Implantation Failure Women', 'organization': {'class': 'OTHER', 'fullName': 'Shanghai First Maternity and Infant Hospital'}, 'officialTitle': 'Anticoagulation Therapies Effect on the Endometrial Blood Flow and Pregnancy Outcomes in Unexplained Recurrent Implantation Failure Women', 'orgStudyIdInfo': {'id': 'ShanghaiFMIH-uRIF'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Group A', 'description': 'Patients who received a daily dose of 75mg LDA per day after menstruation prior to ET.', 'interventionNames': ['Drug: Low dose aspirin']}, {'label': 'Group B', 'description': 'Patients who received a daily dose of 5000u LMWH after menstruation prior to ET.', 'interventionNames': ['Drug: Low molecular weight heparin']}, {'label': 'Group C', 'description': 'Patients who received a daily dose of 75 mg LDA plus 5000u LMWH after menstruation prior to ET.', 'interventionNames': ['Drug: Low dose aspirin plus low molecular weight heparin']}, {'label': 'Group D', 'description': 'Patients who did not receive any treatment.', 'interventionNames': ['Drug: no treatment']}], 'interventions': [{'name': 'Low dose aspirin', 'type': 'DRUG', 'description': 'LDA 25mg tid', 'armGroupLabels': ['Group A']}, {'name': 'Low molecular weight heparin', 'type': 'DRUG', 'description': 'LMWH 5000u IH qd', 'armGroupLabels': ['Group B']}, {'name': 'Low dose aspirin plus low molecular weight heparin', 'type': 'DRUG', 'description': 'LDA 25mg tid + LMWH 5000u IH qd', 'armGroupLabels': ['Group C']}, {'name': 'no treatment', 'type': 'DRUG', 'description': 'Patients who did not receive any treatment.', 'armGroupLabels': ['Group D']}]}, 'contactsLocationsModule': {'locations': [{'zip': '200051', 'city': 'Shanghai', 'country': 'China', 'facility': 'Shanghai first Maternity and Infant health hospital, Tong Ji University', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}], 'centralContacts': [{'name': 'Shihua Bao, PhD', 'role': 'CONTACT', 'email': 'baoshihua@tongji.edu.cn', 'phone': '86-21-20261430', 'phoneExt': '2012'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Shanghai First Maternity and Infant Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Shihua Bao', 'investigatorAffiliation': 'Shanghai First Maternity and Infant Hospital'}}}}